Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Crinetics Pharmaceuticals (CRNX) over the last 7 years, with Dec 2024 value amounting to $92.7 million.

  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) rose 17.67% to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year increase of 17.67%. This contributed to the annual value of $92.7 million for FY2024, which is 38.83% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Shares Outstanding (Weighted Average) of $92.7 million as of FY2024, which was up 38.83% from $66.8 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $92.7 million during FY2024, with a 5-year trough of $32.9 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $66.8 million (2023), whereas its average is $71.1 million.
  • Data for Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 44.28% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $32.9 million in 2020, then soared by 44.28% to $47.5 million in 2021, then rose by 13.29% to $53.8 million in 2022, then rose by 24.14% to $66.8 million in 2023, then spiked by 38.83% to $92.7 million in 2024.